2025-06-16-花旗集团-雷迪博士实验室（REDY）_雷迪博士（REDY.BO）_模型更新_12页_504kb

Citigroup Analysis Summary: Dr Reddy (REDY.BO)

Citigroup maintains a Sell rating on Dr Reddy's stock, based on revised financial forecasts and valuation adjustments following concerns about the company's performance. The target price was lowered from Rs1,110 to Rs1,040, reflecting a reduction in the target PE multiple from 26x to 23x for the fiscal year 2027.

The key reasons for the Sell recommendation include the company's heavy reliance on complex generics, which has historically led to execution disappointments and could result in further downward revisions if future performance issues arise. Historical data shows that failed execution on complex generics has frequently impacted earnings and growth expectations, leading to negative adjustments in consensus numbers.

Financially, earnings and growth are projected to stabilize but then decline significantly, with a sharp drop in FY2027E attributed to the gRevlimid impact. The P/E ratio is expected to rise in FY2027E due to lower growth and profitability, while valuation multiples vary by region: India business valued at 28x (discounted due to lower growth), US generics at 18x (discounted for visibility), and other markets at 24x (aligned with peer valuations).

Risks highlight potential upside catalysts, such as surprise launches of high-value molecules in the US, improvements in generic pricing there, or successful cost rationalization efforts, which could support the stock price above the target.

Overall Outlook: The analysis emphasizes ongoing execution risk, with a projected decline in earnings in FY2027E, reinforcing the Sell rating despite minor adjustments for broader market conditions or other factors.